Skip to main content
. 2007 Mar 1;581(Pt 2):431–444. doi: 10.1113/jphysiol.2006.125799

Figure 4.

Figure 4

A, muscle PDC activity before and after 5 h of intravenous saline (CON; ○) or l-carnitine (CARN; •) infusion accompanied by a 6 h euglycaemic hyperinsulinaemic clamp (the saline/l-carnitine infusion commenced after a 1 h equilibration period), and 18 h after the end of the respective infusion visits (24 h). Values represent means ±s.e.m. (n = 7). ††P < 0.01, significantly greater than pre CON and CARN infusion value, and significantly less than post CON and CARN infusion value. *P < 0.05, CARN significantly less than corresponding CON value. B, muscle glycogen content before and after 5 h of intravenous saline (CON; ○) or l-carnitine (CARN; •) infusion accompanied by a 6 h euglycaemic hyperinsulinaemic clamp (the saline/l-carnitine infusion commenced after a 1 h equilibration period), and 18 h after the end of the respective infusion visits (24 h). Values represent means ±s.e.m. (n = 7). †P < 0.05, ††P < 0.01, †††P < 0.001, significantly different than pre infusion value. **P < 0.01, CARN significantly greater than corresponding CON value. From Stephens et al. (2006b), reproduced with permission; © 2006, The Endocrine Society.